Agenus Teams Up With NewVac On Russian Deal
This article was originally published in The Pink Sheet Daily
The Massachusetts biotech has found a partner to commercialize its cancer vaccine in Russia and develop the drug for other indications.
You may also be interested in...
Agenus Extends Cash Runway In GSK Partnership Expansion
Agenus will have sufficient cash to last through 2013 as it focuses on furthering its immunotherapeutics, including HerpV for genital herpes and Prophage Series G vaccines for glioma.
Deals Of The Week: Amgen/Watson, Baxter/Momenta, Takeda/Intellikine
Biosimilars took center stage during the last two weeks of 2011, as Amgen and Watson and then Baxter and Momenta followed up on the collaboration between Biogen Idec and Samsung BioLogics earlier in the month.
Antigenics’ Oncophage Approved In Russia, First Therapeutic Cancer Vaccine To Enter Marketplace
The biologic will launch this summer at a price in the lower range of $50,000-$100,000/patient/year, the typical cost of new cancer drugs in Russia, firm tells “The Pink Sheet” DAILY.